FDA expands types of acceptable confirmatory evidence in new guidance
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsComplianceNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyResearch, Design and Development